Review article · 2018 · Open access

Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs

Massimo Gadina, Catrina Johnson, Daniella M. Schwartz, Michael Markus Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul S. Changelian, Arian D. J. Laurence, John J. O’Shea

Journal of Leukocyte Biology, 104(3), 499–514 · Published 12 July 2018 · DOI 10.1002/jlb.5ri0218-084r

Open PDFView at the publisherCite this paper

In brief

“Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs” is a 2018 review article by Massimo Gadina and 8 co-authors, published in Journal of Leukocyte Biology. OpenAlex counts 167 citations as of 21 November 2026. It is open access: the full text is free to read at Journal of Leukocyte Biology.

Citations
167
Most cited in
2020 (32)
Field-weighted impact
2.10
References
197
Authors
9

Abstract

In this era, it is axiomatic that cytokines have critical roles in cellular development and differentiation, immune homeostasis, and host defense. Equally, dysregulation of cytokines is known to contribute to diverse inflammatory and immune-mediated disorders. In fact, the past 20 years have witnessed the rapid translation of basic discoveries in cytokine biology to multiple successful biological agents (mAbs and recombinant fusion proteins) that target cytokines. These targeted therapies have not only fundamentally changed the face of multiple immune-mediated diseases but have also unequivocally established the role of specific cytokines in human disease; cytokine biologists have many times over provided remarkable basic advances with direct clinical benefit. Numerous cytokines rely on the JAK-STAT pathway for signaling, and new, safe, and effective small molecule inhibitors have been developed for a range of disorders. In this review, we will briefly summarize basic discoveries in cytokine signaling and briefly comment on some major unresolved issues. We will review clinical data pertaining to the first generation of JAK inhibitors and their clinical indications, discuss additional opportunities for targeting this pathway, and lay out some of the challenges that lie ahead.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Gadina, M., Johnson, C., Schwartz, D. M., Bonelli, M. M., Hasni, S., Kanno, Y., Changelian, P. S., Laurence, A. D. J., & O’Shea, J. J. (2018). Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. Journal of Leukocyte Biology, 104(3), 499–514. https://doi.org/10.1002/jlb.5ri0218-084r

MLA 9

Gadina, Massimo, et al. “Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs.” Journal of Leukocyte Biology, vol. 104, no. 3, 2018, pp. 499–514. https://doi.org/10.1002/jlb.5ri0218-084r.

Chicago

Gadina, Massimo, Catrina Johnson, Daniella M. Schwartz, Michael Markus Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul S. Changelian, Arian D. J. Laurence, and John J. O’Shea. 2018. “Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs.” Journal of Leukocyte Biology 104 (3): 499–514. https://doi.org/10.1002/jlb.5ri0218-084r.

Harvard

Gadina, M. et al. (2018) ‘Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs’, Journal of Leukocyte Biology, 104(3), pp. 499–514. doi:10.1002/jlb.5ri0218-084r.

IEEE

M. Gadina et al., “Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs,” Journal of Leukocyte Biology, vol. 104, no. 3, pp. 499–514, 2018, doi: 10.1002/jlb.5ri0218-084r.

BibTeX

@article{gadina2018translational,
  title     = {{Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs}},
  author    = {Gadina, Massimo and Johnson, Catrina and Schwartz, Daniella M. and Bonelli, Michael Markus and Hasni, Sarfaraz and Kanno, Yuka and Changelian, Paul S. and Laurence, Arian D. J. and O’Shea, John J.},
  journal   = {Journal of Leukocyte Biology},
  year      = {2018},
  volume    = {104},
  number    = {3},
  pages     = {499--514},
  doi       = {10.1002/jlb.5ri0218-084r},
  url       = {https://doi.org/10.1002/jlb.5ri0218-084r}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201311
201877
20191919
20203232
20213131
20222626
20231212
20241616
20251212
20261111

Its field-weighted citation impact is 2.10: it has been cited 2.10 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions

  • JAK/STAT signaling
  • JAK inhibitors
  • cytokine signaling
  • cytokines
  • small molecule inhibitors
  • immune-mediated diseases
  • inflammatory diseases
  • targeted therapy

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Gadina, M., Johnson, C., Schwartz, D. M., Bonelli, M. M., Hasni, S., Kanno, Y., Changelian, P. S., Laurence, A. D. J., & O’Shea, J. J. (2018). Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. Journal of Leukocyte Biology, 104(3), 499–514. https://doi.org/10.1002/jlb.5ri0218-084r

How many times has this paper been cited?

167 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Leukocyte Biology: sign in and open the PDF from this page.

Who wrote this paper?

Massimo Gadina, Catrina Johnson, Daniella M. Schwartz, Michael Markus Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul S. Changelian, Arian D. J. Laurence, John J. O’Shea.

What is the DOI of this paper?

10.1002/jlb.5ri0218-084r, permanently at https://doi.org/10.1002/jlb.5ri0218-084r. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.